{"id":"https://genegraph.clinicalgenome.org/r/1b622fcf-ada8-40c1-8e96-e513541d37a9v1.1","type":"EvidenceStrengthAssertion","dc:description":"*NUS1* was first reported in relation to autosomal dominant progressive myoclonus epilepsy in 2017 (PMID: 29100083) when Hamdan et al. described three patients with myoclonic seizures, disorders of intellectual development and tremor, or ataxia. This gene encodes the Nogo-B receptor (NgBR), a subunit of cis-prenyltransferase (cis-PTase), and is involved in the synthesis of dolichol, which is necessary for protein glycosylation [It interacts with dehydrodolichyl diphosphate synthase complex subunit (DHDDS) and promotes cis-prenyltransferase (cis-PTase) activity] (PMID: 19723497, PMID: 21572394). Notably, in 2014 (PMID: 25066056) autosomal recessive inheritance of *NUS1* p.R290H variant was linked to the congenital disorder of glycosylation type1Iaa presenting with congenital scoliosis, severe neurological impairment, refractory epilepsy, hearing deficit, and visual impairment with discrete bilateral macular lesions. The studies reported in this curation detected patients with heterozygous loss of function variants in *NUS1*, presenting with variable clinical presentations including different seizure types, varying degrees of developmental delay, and the presence of myoclonus or other motor phenotypes. \n\nSeveral non-sense, frameshift, and splice site variants, as well as copy number variations (CNVs) affecting all or part of *NUS1*, are reported in more than 25 probands across 15 publications (PMIDs: 29100083, 3165617, 32485575, 33111323, 32959737, 3453230, 33731878, 33798445, 35949226, 37249665, 38291835, 37470039, 38520610, 39772664, 39934081). Most reported variants are de novo with the exception of the familial c.22_23insA (PMID:32485575), which is segregated in 5 individuals.\n\nIn summary, there is definitive evidence to support the relationship between *NUS1* and autosomal dominant progressive myoclonus epilepsy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Epilepsy GCEP on the meeting date 05/20/2025 (SOP Version 11). \n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/1b622fcf-ada8-40c1-8e96-e513541d37a9","GCISnapshot":"https://genegraph.clinicalgenome.org/r/e50efc63-0235-4c75-a4ab-6c129485a117","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:otherTextChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/e50efc63-0235-4c75-a4ab-6c129485a117_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2025-09-30T19:26:43.427Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/e50efc63-0235-4c75-a4ab-6c129485a117_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2025-05-20T16:00:00.000Z","role":"Approver"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e50efc63-0235-4c75-a4ab-6c129485a117_experimental_evidence_line","type":"EvidenceLine","specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/e50efc63-0235-4c75-a4ab-6c129485a117_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/456ba419-7aad-49b2-aae4-fefeab1191bc","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/456ba419-7aad-49b2-aae4-fefeab1191bc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33731878","allele":{"id":"https://genegraph.clinicalgenome.org/r/a9809ff1-18bc-40c4-9215-05c40a5aec8e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.734G>T (p.Gly245Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365537346"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/456ba419-7aad-49b2-aae4-fefeab1191bc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient fibroblast lines  were used to investigate potential glycosylation defects, intralysosomal cholesterol storage, and the impact of variants on NgBR protein levels. Western blot analysis revealed a 50% reduction in the steady-state level of NgBR protein in patient cell lines, supporting the likelihood of the variant causing loss of function either through altered transcript abundance or decreased protein stability. Quantitative reverse transcription polymerase chain reaction (RT-PCR) of cells showed a 30% reduction in NUS1 transcript abundance. Cloning and sequencing of amplicons indicate 64% of NUS1 messenger RNA (mRNA) is wild type (WT), while 36% contains the variant The recently published crystal structures of the NUS1 and DHDDS gene products suggest the substitution of valine for glycine at position 245  likely disrupts the stability/folding of three ß-sheet structures that converge near that position","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/44d4a2ee-6181-4903-b121-9467470db7f3","type":"EvidenceLine","dc:description":"conservative scoring ","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/44d4a2ee-6181-4903-b121-9467470db7f3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31656175","allele":{"id":"https://genegraph.clinicalgenome.org/r/87a0e453-6a7f-4e87-ba69-591a60a33e11","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.691+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365537233"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/44d4a2ee-6181-4903-b121-9467470db7f3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"cDNA from  lymphoblastoid cell lines, revealed that the mutant allele has a 1-base alternation in the splice donor site (chr6:118,015,344) creating a new splice donor site of GT in exon 3 (chr6:118,015,253), resulting in a 91-bp deletion in the NUS1 exon 3 {c.601_691del:p.(Arg202Glnfs*9)}. TA-cloning of the short RT-PCR product confirmed the same event in the mutant allele and produces a PTC at chr6:118,024,795 (73-bp upstream of the 3′ exon-exon junction). Quantitative analysis using RT-PCR  showed that the relative gene expression levels of NUS1 was slightly reduced in the patient's LCLs, with possible minor recovery following cycloheximide treatment . These results support the prediction that the transcribed mRNA of the mutant allele is only partially subjected to NMD.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/5f880085-ad30-47b0-9220-ca8f52239af4","type":"EvidenceLine","dc:description":"conservative scoring","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5f880085-ad30-47b0-9220-ca8f52239af4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100083","allele":{"id":"https://genegraph.clinicalgenome.org/r/28ef5cfc-c52a-4ac4-948c-9d67cfe1a4f8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.743del (p.Asp248AlafsTer4)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658657608"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/3907fe64-d3d5-47c8-891d-9c9304c1a6cd","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3907fe64-d3d5-47c8-891d-9c9304c1a6cd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32485575","allele":{"id":"https://genegraph.clinicalgenome.org/r/72be275f-eec9-4d79-82b4-885a13de3ea5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.22_23insA (p.Val8AspfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695206871"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/3907fe64-d3d5-47c8-891d-9c9304c1a6cd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Immunoblotting using anti-Nogo B receptor (NUS1) antibody showed that the exogenous NUS1 bands were detected in HEK cells transfected with the NUS1-WT vector, but only scarcely detected in those with the NUS1-mutant vector. Immunofluorescence and subcellular proteome analysis showed that normal NUS1 protein localizes at the plasma membrane, while NUS1-mutant protein was seen in the cytosol ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/142a5208-3e54-44da-b9ea-ecb2616a17ad","type":"EvidenceLine","dc:description":"conservative scoring ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/142a5208-3e54-44da-b9ea-ecb2616a17ad_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39934081","allele":{"id":"https://genegraph.clinicalgenome.org/r/691d8275-c193-4328-9534-77110b9c46ad","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.865C>T (p.Gln289Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365537653"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/3702f3b4-d0f1-4e75-809c-945f4bcf8c4b","type":"EvidenceLine","dc:description":"Conservative scoring ","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3702f3b4-d0f1-4e75-809c-945f4bcf8c4b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33798445","allele":{"id":"https://genegraph.clinicalgenome.org/r/11633362-c5dd-438d-a4c3-8a3c8ab3a30b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.310del (p.Val104Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695206873"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/3702f3b4-d0f1-4e75-809c-945f4bcf8c4b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Fibroblast cells by western blotting revealed decreased amount of NUS1 in cells from individuals with PME compared to control subjects, implying the presence of nonsense-mediated mRNA decay and/or instability of the truncated proteins.  In order to evaluate the consequence of the reduced cisPTase activity in fibroblast cells, the glycosylation status of ICAM1 and LAMP1, established markers for N-glycosylation defects, was examined. Altered ICAM1 and LAMP1 expression and migration were detected by western blot analysis. Free cholesterol levels, an additional consequence of NUS1 dysfunction in cells were also analysed . Fibroblasts were stained with filipin and free cholesterol pools were examined. Fibroblasts exhibited increased accumulation of free cholesterol compared to controls","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/aedf4fd3-fff2-4178-839a-b4823a314870","type":"EvidenceLine","dc:description":"conservative prediction","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aedf4fd3-fff2-4178-839a-b4823a314870_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100083","allele":{"id":"https://genegraph.clinicalgenome.org/r/3b6b9f2a-5d03-4cee-9e1d-2066ab240cce","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"GRCh38 6q22.2(chr6:118013073-118014377)x1"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9e0f5df6-ea9d-44bf-9f7c-f41321ec9ca3","type":"EvidenceLine","dc:description":"Conservative scoring ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e0f5df6-ea9d-44bf-9f7c-f41321ec9ca3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34532305","allele":{"id":"https://genegraph.clinicalgenome.org/r/7ce8fd3d-47c7-44ac-8b1f-66ffd5efa1c4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.51_54del (p.Leu18ThrfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695206872"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/3d16c33c-9666-43a8-91e8-2411e1c39ba9","type":"EvidenceLine","dc:description":"conservative scoring ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3d16c33c-9666-43a8-91e8-2411e1c39ba9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33731878","allele":{"id":"https://genegraph.clinicalgenome.org/r/41679e9b-6fdd-41bc-88f0-0e6106229479","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.415+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365536583"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/645593f2-4c2c-4215-9080-425bb03b256e","type":"EvidenceLine","dc:description":"conservative scoring ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/645593f2-4c2c-4215-9080-425bb03b256e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33111323","allele":{"id":"https://genegraph.clinicalgenome.org/r/c2cdcf84-2f49-4777-b4dc-9cb86f96d21c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.692-1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365537243"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e6aef83c-540c-4ad1-b70e-1f9d23557dd3","type":"EvidenceLine","dc:description":"conservative scoring ","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e6aef83c-540c-4ad1-b70e-1f9d23557dd3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37470039","allele":{"id":"https://genegraph.clinicalgenome.org/r/ac117cd8-3815-438e-8fb1-7b504c9d9689","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.791+6T>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695198323"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e6aef83c-540c-4ad1-b70e-1f9d23557dd3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RNA sequencing disclosed exon 4 skiping / minigel assay confirming findings ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/efc734ec-d78a-400f-a3c0-b52def4ecbbd","type":"EvidenceLine","dc:description":"Conservative scoring","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/efc734ec-d78a-400f-a3c0-b52def4ecbbd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32959737","allele":{"id":"https://genegraph.clinicalgenome.org/r/faeb7d43-1327-4a42-8500-8c0e102c0497","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.104G>A (p.Trp35Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365535906"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/7629bc9b-f684-4cb9-9f17-df86e098a67a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7629bc9b-f684-4cb9-9f17-df86e098a67a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37249665","allele":{"id":"https://genegraph.clinicalgenome.org/r/11aacad7-c24f-465c-a56c-65fda0a2d646","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.302T>A (p.Met101Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365536317"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e50efc63-0235-4c75-a4ab-6c129485a117_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a2685f74-6400-4d03-9f9d-221f694fc18e_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32485575","rdfs:label":"Family described in PMID: 32485575","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/a2685f74-6400-4d03-9f9d-221f694fc18e","type":"Family","rdfs:label":"Family described in PMID: 32485575","member":{"id":"https://genegraph.clinicalgenome.org/r/5bba3c8a-510d-4d38-8084-c9c5d811bf8a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32485575","rdfs:label":"Patient 2 et al. Araki","ageType":"AgeAtReport","ageUnit":"Years","ageValue":42,"allele":{"id":"https://genegraph.clinicalgenome.org/r/72be275f-eec9-4d79-82b4-885a13de3ea5"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0020221","obo:HP_0001952","obo:HP_0003119","obo:HP_0002080","obo:HP_0002322"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3907fe64-d3d5-47c8-891d-9c9304c1a6cd_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":5,"phenotypes":["obo:HP_0001337","obo:HP_0001251"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/5bba3c8a-510d-4d38-8084-c9c5d811bf8a"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/133ade93-8bd1-45e1-9bbe-d5b7ae315338","type":"EvidenceLine","dc:description":"Conservative scoring","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/133ade93-8bd1-45e1-9bbe-d5b7ae315338_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39772664","allele":{"id":"https://genegraph.clinicalgenome.org/r/ec3e51df-4183-4da2-9586-78e90101679e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.349_353del (p.Ile117GlufsTer15)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3060597765"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/375f9010-1d8d-44d1-ae4d-ec8ab71f4270","type":"EvidenceLine","dc:description":"conservative scoring ","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/375f9010-1d8d-44d1-ae4d-ec8ab71f4270_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38520610","allele":{"id":"https://genegraph.clinicalgenome.org/r/c2b16f96-1fba-4dd0-aca4-3aeb9996621c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.792-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365537484"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/375f9010-1d8d-44d1-ae4d-ec8ab71f4270_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro splicing assays /A minigene splicing assay was performed to analyze the effect of NUS1 variant c.792-2A > G in intron 4 on RNA splicing. A 2404 bp fragment of the NUS1 gene, including exons 3–4, partial exon 5, and introns 3–4, was amplified and cloned into the pCDNA3.1(+) plasmid to construct a minigene. The variant was generated with directed mutagenesis (#c214; Vazyme) using PCR (forward: 5’-GTGTTTTCTTTTCGGCTCTTTGCCTTCCCACCTAAAC-3’; reverse: 5’-CAAAGAGCCGAAAAGAAAACACGGGGGGAGAAAAG-3’). The sequences and correct orientations of all constructs were validated using Sanger sequencing. Minigene constructs were transfected into HEK293T cells for 24 h. Total RNA was extracted from the cells using TRIzol reagent (#15,596,018; Life Technologies, Carlsbad, CA, USA), and complementary DNA (cDNA) was synthesized according to the manufacturer’s instructions (#FSK-101; Toyobo, Japan). The fragment, spanning from exon 3 to exon 5, was amplified using PCR (forward: 5’-GCCATTTGGCAGTGAAGGT-3’; reverse: 5’-GGTCACTAAGAAGGACTGAAC-3’), separated with 2% agarose gel electrophoresis, and verified using Sanger sequencing.The inclusion of the intron 4 resulted in the introduction of a TAA stop codon between exons 4 and 5, leading to the premature termination of protein translation.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/dbbd910b-32f1-43d6-95fc-5196f92828b2","type":"EvidenceLine","dc:description":"conservative scoring","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dbbd910b-32f1-43d6-95fc-5196f92828b2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100083","allele":{"id":"https://genegraph.clinicalgenome.org/r/96ebde3b-1972-4ad7-88c1-332cde117675","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.128_141dup (p.Val48ProfsTer7)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658657609"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/458e461a-e5fb-49bb-921c-fecb20562b77","type":"EvidenceLine","dc:description":"conservative scoring ","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/458e461a-e5fb-49bb-921c-fecb20562b77_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33731878","allele":{"id":"https://genegraph.clinicalgenome.org/r/86438f4b-9c08-4cef-a5a2-95c62a69358b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.752T>G (p.Leu251Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365537384"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/458e461a-e5fb-49bb-921c-fecb20562b77_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Fibroblast lines were used to investigate potential glycosylation defects, intralysosomal cholesterol storage, and the impact of variant on NgBR protein levels. Western blot analysis revealed a 50% reduction in the steady-state level of NgBR protein in patient cell lines, supporting the likelihood these variants cause loss of function either through altered transcript abundance or decreased protein stability. No reduction in NUS1 transcript abundance was noted and 58% of the mRNA was WT. However, the variant generates a premature termination codon at position 251 and gel-based analyses of transcripts revealed a shorter species, indicating aberrant mRNA may be degraded by nonsense-mediated decay. A lower molecular weight band also observed in the NgBR western blot likely represents the truncated protein. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/b1f1c12e-90bf-4f67-aa01-96484b68565d","type":"EvidenceLine","dc:description":"conservative scoring ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b1f1c12e-90bf-4f67-aa01-96484b68565d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38291835","allele":{"id":"https://genegraph.clinicalgenome.org/r/ecb8a5a0-dc5a-4a51-8aca-4656edf09583","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.472G>T (p.Glu158Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365536735"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/db92abec-e727-40bf-8537-17ccd19e026b","type":"EvidenceLine","dc:description":"conservative scoring ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db92abec-e727-40bf-8537-17ccd19e026b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38520610","allele":{"id":"https://genegraph.clinicalgenome.org/r/7f5bf449-f92b-4229-b30f-5e86b115af68","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.868C>T (p.Arg290Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365537661"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/db92abec-e727-40bf-8537-17ccd19e026b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Recombinant Plasmid Construction/Cell Culture and Transfection/Western Blotting/Drosophila model\nAll Drosophila were raised at 25 °C and 60% humidity in a 12-hour light/dark cycle on standard cornmeal food. UAS-Tango14-RNAi (FBgn0031312) and Tango14R290C/+ (CG4775-W276C/Seizure Behavior Test\nThe bang-sensitive (BS) test was performed on Drosophila 3–5 d after eclosion to assess seizure-like behavior, as previously reported/Electrophysiological assay/HEK293T cells. The p.R290C mutant, compared with WT, exhibited faster degradation of its protein after 4 h of CHX treatment/Knockdown of NUS1 activated the unfolded protein reaction/Knockdown of Tango14 and knock-in of the R290C variant increased seizure-like activities and activated the UPR in Drosophila./eficiency of Tango14 in Drosophila increased the excitation of neurons, and this increase was more significant in Tango14 KI Drosophila./nock-in of the R290C variant of Tango14 in Drosophila resulted in significantly decreased pupal length compared to that in KD and WT Drosophila (Fig. 6D). Thus, the KD and KI of Tango14 disturbed larval and pupal size determination during morphogenesis","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/09040fdd-59e7-442b-aa8b-8628893984c0","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/09040fdd-59e7-442b-aa8b-8628893984c0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35949226","allele":{"id":"https://genegraph.clinicalgenome.org/r/7f5bf449-f92b-4229-b30f-5e86b115af68"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6d68012e-75c9-4a85-b32c-f80a7a6b8058","type":"EvidenceLine","dc:description":"This variant was downgraded due to conservative scoring. This proband also has a variant in NM_001130438.3(SPTAN1):c.2311G>T (p.Glu771Ter) that was maternally inherited. ","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6d68012e-75c9-4a85-b32c-f80a7a6b8058_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31656175","allele":{"id":"https://genegraph.clinicalgenome.org/r/87a0e453-6a7f-4e87-ba69-591a60a33e11"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/6d68012e-75c9-4a85-b32c-f80a7a6b8058_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"cDNA from  lymphoblastoid cell lines, revealed that the mutant allele has a 1-base alternation in the splice donor site (chr6:118,015,344) creating a new splice donor site of GT in exon 3 (chr6:118,015,253), resulting in a 91-bp deletion in the NUS1 exon 3 {c.601_691del:p.(Arg202Glnfs*9)}. TA-cloning of the short RT-PCR product confirmed the same event in the mutant allele and produces a PTC at chr6:118,024,795 (73-bp upstream of the 3′ exon-exon junction). Quantitative analysis using RT-PCR  showed that the relative gene expression levels of NUS1 was slightly reduced in the patient's LCLs, with possible minor recovery following cycloheximide treatment . These results support the prediction that the transcribed mRNA of the mutant allele is only partially subjected to NMD.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/088e0d17-de1f-4b6d-ba2d-2c270d975984","type":"EvidenceLine","dc:description":"decided not to score since the patient had no epileptic presentations ","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/088e0d17-de1f-4b6d-ba2d-2c270d975984_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33798445","allele":{"id":"https://genegraph.clinicalgenome.org/r/31dbb5bc-dc24-4121-b88b-d235e4985b6f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138459.5(NUS1):c.740dup (p.Asp248GlyfsTer15)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695206915"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/088e0d17-de1f-4b6d-ba2d-2c270d975984_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Analysis of fibroblast cells by western blotting revealed decreased amount of NUS1 in cells from individuals with PME compared to control subjects, implying the presence of nonsense-mediated mRNA decay and/or instability of the truncated proteins In addition the amount of DHDDS appeared to be decreased, in line with the predicted truncated NUS1 product that is missing the interface region for heterodimerization with DHDDS and consequently DHDDS instability. CisPTase activity in cells was drastically decreased, demonstrating that lower protein levels directly affect enzymatic turnover rates. Established markers for N-glycosylation defects were examined. \n and altered ICAM1 and LAMP1 expression and migration were detected by western blot analysis   Free cholesterol levels, an additional consequence of NUS1 dysfunction in cells were also examined after fibroblasts staining with filipin where increased accumulation of free cholesterol compared to controls was detected .","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":11889,"specifiedBy":"GeneValidityCriteria11","strengthScore":12,"subject":{"id":"https://genegraph.clinicalgenome.org/r/T5IQfH5WhSk","type":"GeneValidityProposition","disease":"obo:MONDO_0020074","gene":"hgnc:21042","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_e50efc63-0235-4c75-a4ab-6c129485a117-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}